Post-marketing experiences with belimumab in the treatment of SLE patients.
| Autor: | Askanase AD; Department of Medicine, Columbia University Medical Center, 630 West 168th Street, P&S 10-508, New York, NY 10032, USA. Electronic address: ada20@columbia.edu., Yazdany J; Department of Medicine, University of California, San Francisco, School of Medicine, 1001 Potrero Avenue, SFGH 30, San Francisco, CA 94143, USA., Molta CT; GlaxoSmithKline, 5 Crescent Drive, Philadelphia, PA 10112, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Rheumatic diseases clinics of North America [Rheum Dis Clin North Am] 2014 Aug; Vol. 40 (3), pp. 507-17, viii. Date of Electronic Publication: 2014 Jun 03. |
| DOI: | 10.1016/j.rdc.2014.04.007 |
| Abstrakt: | Belimumab (Benlysta) is a human recombinant monoclonal antibody that targets and inhibits soluble B-lymphocyte stimulator, also known as B-cell activating factor, a proliferation and survival factor for B cells. The published clinical trials data showed that in patients with active systemic lupus erythematosus (SLE), belimumab effectively reduced peripheral B-cell levels and improved disease activity. This article reviews the belimumab clinical trials and the post-marketing experience with belimumab in the treatment of those lupus patients with persistent active disease despite current standard of care (SOC) therapy. (Copyright © 2014 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|